Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity

Menopausal hormone therapy with estrogen plus progestin or estrogen alone (for women with prior hysterectomy) is still used by millions of women for climacteric symptom management throughout the world. Until 2002, hormone therapy influence on cancer risk and other chronic diseases was determined through observational study reports. Since then, results from the Women’s Health Initiative randomized, placebo-controlled hormone therapy trials have...